Burzynski Research Institute (Burzynski Research Institute) Valuation Rank

View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Burzynski Research Institute Valuation Rank Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Burzynski Research Institute (Burzynski Research Institute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

9432 Katy Freeway, Houston, TX, USA, 77055

Website

http://www.burzynskiresearch.com

Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.

Executives

Monika Szopa-paszkowiak	director	9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff	director	9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski	director, 10 percent owner	9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood	director	9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski	officer: Secretary and Treasurer	9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski	director	9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki	officer: VP of Clinical Trials	9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll	director	9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski	director, 10 percent owner, officer: President	9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson	officer: Chief Financial Officer	9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055